Co-inhibition of immunoproteasome subunits LMP2 and LMP7 is required to block autoimmunity.
- Basler M Biotechnology Institute Thurgau (BITg) at the University of Konstanz, Kreuzlingen, Switzerland michael.basler@uni-konstanz.de marcus.groettrup@uni-konstanz.de.
- Lindstrom MM Principia Biopharma, South San Francisco, CA, USA.
- LaStant JJ Principia Biopharma, South San Francisco, CA, USA.
- Bradshaw JM Principia Biopharma, South San Francisco, CA, USA.
- Owens TD Principia Biopharma, South San Francisco, CA, USA.
- Schmidt C Division of Immunology, Department of Biology, University of Konstanz, Konstanz, Germany.
- Maurits E Leiden Institute of Chemistry, Leiden University, Leiden, The Netherlands.
- Tsu C Takeda Pharmaceuticals International Co., Cambridge, MA, USA.
- Overkleeft HS Leiden Institute of Chemistry, Leiden University, Leiden, The Netherlands.
- Kirk CJ Kezar Life Sciences, South San Francisco, CA, USA.
- Langrish CL Principia Biopharma, South San Francisco, CA, USA.
- Groettrup M Biotechnology Institute Thurgau (BITg) at the University of Konstanz, Kreuzlingen, Switzerland michael.basler@uni-konstanz.de marcus.groettrup@uni-konstanz.de.
- 2018-10-04
Published in:
- EMBO reports. - 2018
autoimmune disease
immunoproteasome
immunoproteasome inhibitor design
proteasome
Animals
Autoimmunity
Cell Differentiation
Cell Membrane Permeability
Colitis
Cytokines
Dextran Sulfate
Encephalomyelitis, Autoimmune, Experimental
Epitopes
Histocompatibility Antigens Class I
Mice, Inbred C57BL
Proteasome Endopeptidase Complex
Proteasome Inhibitors
Protein Subunits
Spleen
Th17 Cells
English
Cells of hematopoietic origin express high levels of the immunoproteasome, a cytokine-inducible proteasome variant comprising the proteolytic subunits LMP2 (β1i), MECL-1 (β2i), and LMP7 (β5i). Targeting the immunoproteasome in pre-clinical models of autoimmune diseases with the epoxyketone inhibitor ONX 0914 has proven to be effective. ONX 0914 was previously described as a selective LMP7 inhibitor. Here, we show that PRN1126, developed as an exclusively LMP7-specific inhibitor, has limited effects on IL-6 secretion, experimental colitis, and experimental autoimmune encephalomyelitis (EAE). We demonstrate that prolonged exposure of cells with ONX 0914 leads to inhibition of both LMP7 and LMP2. Co-inhibition of LMP7 and LMP2 with PRN1126 and LMP2 inhibitors LU-001i or ML604440 impairs MHC class I cell surface expression, IL-6 secretion, and differentiation of naïve T helper cells to T helper 17 cells, and strongly ameliorates disease in experimental colitis and EAE. Hence, co-inhibition of LMP2 and LMP7 appears to be synergistic and advantageous for the treatment of autoimmune diseases.
- Language
-
- English
- Open access status
- green
- Identifiers
-
- DOI 10.15252/embr.201846512
- PMID 30279279
- Persistent URL
- https://sonar.ch/global/documents/223795
Export to…
Statistics
Document views: 127
File downloads:
- Full-text: 0